Amneal Pharmaceuticals Releases 2024 ESG Report Highlighting Business Initiatives

Reuters
06/27
Amneal Pharmaceuticals Releases 2024 ESG Report Highlighting Business Initiatives

Amneal Pharmaceuticals Inc. has released its 2024 Responsible Business Report, detailing progress in environmental, social, and governance $(ESG)$ initiatives. The report outlines efforts to enhance healthcare access, promote environmental sustainability, and support workforce development. Key highlights include the introduction of a new ESG framework structured around societal impact, environmental impact, and people & practices. In 2024, Amneal filled over 162 million prescriptions in the U.S., launched 22 new generic products, and addressed drug shortages by producing over 10 critical injectable medicines. Environmental efforts included transitioning a manufacturing facility in India from coal to biomass, reducing CO₂ emissions by 1,600 tons annually, and supporting tree planting initiatives. The company also launched a global talent development framework and reported an increase in employee engagement. The full report aligns with global standards and is available on Amneal's website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amneal Pharmaceuticals Inc. published the original content used to generate this news brief on June 26, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10